LP
About
LTR Pharma is a clinical‑stage biopharmaceutical company developing an intranasal PDE5 inhibitor therapy for erectile dysfunction. The company progresses through regulatory pathways and clinical development globally, including early access schemes in Australia and preparations for US FDA approval. LTR Pharma maintains strategic partnerships to support nasal spray development, including a co‑development agreement with Aptar Pharma.
Position in the VCSift Database
- • 3,884 investors in VCSift focus on the healthtech sector.
- • 235 investors are based in Brisbane, Queensland, Australia.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Sectors
- healthtech
- Location
- Brisbane, Australia
Contact Information
Find more investors like LTR
Search Investors